A warning from the US Food and Drug Administration regarding the possible association of blindness with weight loss drugs.
The US Food and Drug Administration has ordered updated safety warnings for widely used GLP-1 drugs after identifying a potential increased risk of a rare but serious eye disease that can cause permanent vision loss.
The FDA's new warning includes all drugs belonging to the group of glucagon-like peptide 1 (GLP-1) receptor agonists. These drugs are widely used to treat type 2 diabetes and obesity. Among the well-known drugs of this group are Ozempi, Vegs, Mongero and Zepbound.